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ABSTRACT 
The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as 
an adjunct to antidepressant in treatment-resistant depression. Fourteen patients, who have not 
responded to 40 mg of escitalopram, received intranasal synthetic oxytocin during 4 weeks, in 
association with antidepressant. This is the first open trial study suggesting OT in association 
with escitalopram significantly reduced scores on Hamilton Depression Rating Scale. 
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The nonapeptide oxytocin (OT) is implicated in social affiliation, sexual and maternal-infant 
bonding, anxiety, mood, feeding control and memory. It is also involved in the regulation of 
emotions, and improves cooperation altruism, and trust in a variety of experimental context [1]. 
There are also speculations that some of the symptoms commonly reported in depression (social 
withdrawal, reduced appetite, cognitive impairment) may reflect dysregulation of OT functions. 
There are relatively few data on plasma OT levels in depression. Discrepancies have been 
reported. Periphery OT levels were found to be reduced, increased or unchanged [19,20]. 
Cyranowski et al. (2008) found a dysregulated pattern of peripheral oxytocin among depressed 
woman (n = 17) compared to controls (n = 17). Previously, we reported an association between 
plasma OT levels and anxiety in patients with major depression [22]. A polymorphism of 
oxytocin receptor (OTR) has been associated with major depression (Thompson et al., 2011). 
Recently, no association was observed between OTR genes (rs 53576, rs 2254298) and 
treatment resistance, response and remission in a sample of 268 patients [14]. 
Preclinical evidence indicates that OT can influence activity of serotonin system, which may 
related to the antidepressant effects of SSRIs [9]. Emiliano et al. [5] have demonstrated overlap 
of OT-labelled neurons and 5-HTT-labelled fibers in the parvicellular, magnocellular, dorsal and 
posterior subdivisions of the PVN and provided neuroanatomic support for the idea that SSRIs 
therapeutic effects on social affiliation and anxiety may be mediated in part through components 
of the OT system. 
Many data suggest a role for OT as an endogenous antidepressant/anxiolytic hormone [26] and 
support the idea that stimulation of OT receptors inhibits the hypothalamo-pituitary- adrenal 
(HPA) axis [17]. The oxytocin and dopaminergic systems may act in concert to reduce anxiety in 
response to social and environmental stressors. Heinrichs et al. [8] have demonstrated that OT 
insufflation (24 I.U.) and social support during public speaking reduce stress responses. OT 
further has stress-protective effects [28]. Interestingly, OT decreases amygdala reactivity to 
aversive, threat-related faces [2] in males, but increases amygdala reactivity to similar faces in 
females [10]. 
Implicit in these results is potential therapeutic opportunity of targeting the central 
oxytoninergic system in the development of novel anxiolytics for humans. The pathophysiology 
of stress- related diseases, such as depression whereas anxiety disorders, includes both 
endogenous/genetic predisposing factors and a dysregulated response to stress, and 
normalizing the HPA axis is one of the major targets of recent treatments [9]. The aim of the 
present open trial study was to assess the effect of intranasal OT – in association to escitalopram 
– in patients with have not responded to escitalopram, as suggested in a previous case report 
[23]. 
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The study was performed in 14 outpatients with major depression, representing consecutive 
admissions to the Biological Psychiatry and Psychoneuroendocrinolgy Unit of the University of 
Liège, Belgium. The diagnosis of major depressive disorder was based on the DSM-IV criteria 
and the self-questionnaire from the Mini International Neuropsychiatric Interview. Moreover, 
patients had a score of at least 17 on the 17-item Hamilton Depression Rating Scale (HDRS-17). 
Patients have required to have experienced treatment-resistant depression as defined by failure 
of adequate trials of two differents classes of major antidepressants at the recommanded 
maximun doses. Patients had at least a 2-year history of resistant depression. All patients, who 
have not responded to 40 mg of escitalopram at least during 8 weeks, received intranasal 
synthetic oxytocin (Syntocinon1, 1 puff per nostril, each with 4 I.U., twice daily) (Novartis, 
Switzerland) during 4 weeks, as a add-on treatment to 40 mg of escitalopram. The daily dosage 
of 16 I.U. has been chosen according to usual range in other psychiatric diseases. Moreover, a 
recent study has documented that salivary OT levels in normal subjects remained similarly 
elevated for up to 7 h of 16 or 24 I.U [27]. Among the 6 women, 4 were premenopausal and 2 
were postmenopausal. All premenopaus women were investigated during the first phase of the 
menstrual cycle as assessed by the patient-reported date of last menstruation. Patients with 
irregular menses were excluded. All patients were free of medical illness as evidence by history, 
medical examination, ECG, chest X-ray, EEG, and routine laboratory tests. Except their current 
antidepresant, they had also been free of other drugs, including benzodiazepines, for at least 2 
weeks at the time of the study. We used and provided standardised instructions and regular 
monitoring to train participants in administration. Individuals with common cold that result in 
significant nasal congestion were not included in the study. The protocol was approved by the 
Ethical Committee of the University of Liège, Belgium. All patients were fully informed of the 
purpose of the study and gave written consent. 
Clinical assessment was perform before the first day of intranasal oxytocin treatment, and 
repeated each week for four weeks. Depressive and anxiety severity was assessed by the 
Hamilton Depressive Rating Scale (HDRS-17, Hamilton, 1967), and by the State-Trait Anxiety 
Inventory (STAI-A State; [24]), respectively. Clinical Global Impressions Severity of Illness scale 
(CGI-S, [6]) was used to assess the global illness severity. Quality of life was assessed by the 
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q, [4]). 
All the statistical analyses were performed with Statistica (10.1) for Windows. Repeated-
measures analysis of variance (ANOVA) on HDRS-17, STAI-A, CGI-S, and Q-LES-Q was conducted 
with time as within-subject factor. Tukey post-hoc comparisons were used to compare the 
clinical data for the different times. No side effects were reported following treatment with 
chronic OT. 
Results  
The sample included 6 women with a mean age of 48.5 years (S.D. = 13.9) and 8 men with a 
mean age of 44.75 years (S.D. = 9.1). Table 1 details patient baseline clinical status. No statistical 
differences were observed between wash out period and baseline. 
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Table 1. Patients clinical status at baseline. 
 
Measure(n=14) Severity rating scale scores, mean (SD) 
 
HDRS-17  26,13 (5,99) 
STAI-A   64,88 (15,88) 
CGI-S  4,29 (0,95) 
Q-LES-Q  1,75 (0,76) 
 
SD: standard deviation 
 
Post-hoc analysis showed significant differences between day 1 and day 8 (HDRS-17, P < 
0.001; STAI-A, P = 0.04; CGI-S, P = 0.02 and Q-LES-Q, P = 0.046), between day 1 and day 15 
(HDRS-17, P < 0.01; STAI-A, P = 0.015; CGI-S, P = 0.03 and Q-LES-Q, P = 0.044), between day 1 
and day 21 (HDRS-17, P = 0.016; CGI- S < 0.01), and between day 1 and day 28 (HDRS, P < 
0.01; STAI-A, P = 0.04; CGI-S, P < 0.01 and Q-LES-Q, P = 0.014) (Fig. 1). The CGI-S ratings 
decreased from initial visit mean of 4.3 (S.D. = 0.95) to a mean of 2 (S.D. = 1.5) (Fig. 2). 
Discussion 
OT has been proposed as a potential treatment for a wide range of brain disorders: addiction, 
anxiety disorders, autism-spectrum disorders, borderline personality disorders, mood 
disorders and schizophrenia [11]. To our knowledge, this is the first open trial study suggesting 
that OT in association with escitalopram significantly reduced scores on HDRS-17 and STAI-A 
in addition to CGI-improvement scale. Moreover, patients showed improved positive 
evaluations of quality of life. OT was well-tolerated and no adverse effects were reported. The 
main limitation of this open trial is the small sample of subjects with mixed gender and the lack 
of a control group. As OT was given in parallel with escitalopram, the observed effects could be 
due to this combination or to the placebo effect. 
There are limited studies exploring the effect of intranasal OT administration in major 
depression. Pincus et al. [21] have shown that depression is associated with increased 
paralimbic activity during emotional mental attribution of others, appearing to be distincly 
modulated by OT when compared to healthy controls. Recently, in mothers with a diagnosis of 
postnatal depression, OT administrations have been link to improvement of the perception of 
the relationship with the baby [12]. In addition, intranasal OT has impeded the ability to ignore 
task-irrelevant facial expressions of sadness in students with depressive symptoms [3]. 
OT plays a leading role in social neuroscience. The possible molecular mechanisms underlying 
antidepressant/anxiolytic effect of OT could be due to the induction of hippocampal 
neurogenesis, the modulation of amydgala activity and the inhibitory action on the HPA axis 
[13]. OT has a potent antidepressant effect following its secretion in the CNS, including the 
hippocampus and amygdala. In mice, OT induces phosphor- ylation of CREB throught activation 
of MAP kinase signaling and induces neuronal plasticity in the hippocampus [13]. BDNF gene 
expression was also found to be up-regulated in primary culture neurons treated with OT by 
microarray analysis [18]. Furman et al. [7] have shown variant in OTR associated with amygdala 
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volume. The effect of the OXTR polymorphism on amygdala volume may be mediated, in part, by 
exposure to corticosteroids, which with chronic exposure may lead to atrophy of amygdala 
dendrites. It is possible that the efficacy of SSRIs in restoring interest in social interactions is 
due, in part, to their actions on the reward circuit via the OT system [5]. The effects of 
antidepressants on OT levels has become a research subject. A study by Ozsoy et al. [19] 
suggested that serum OT levels were non affected by antidepressant use in patients with 
unipolar and bipolar depression. In contrast, there are other studies proposing that an increase 
in central OT levels may be one of the underlying causes for the activities of serotoninergic 
antidepressants [25]. 
Moreover, the behavioral relevance of intranasal OT in patients and its association with central 
nervous system neuropeptide availability and function remain unclear [15] and complex. 
Caution should remain in force. OT seems to promote aggression or other antisocial behavior in 
some circumstances. Its effects also appear to vary depending on a person’s genetic makeup and 
psychosocial status [16]. In addition, Macdonald and Feifel [11] suggest that incertain clinical 
populations and contexts, OT has heterogeneous subjective effects which may include acute 
anxiogenesis. 
Findings should be replicated and extended in a larger samples and a randomized placebo-
controlled trials, controlling age, gender, and stage of menstrual cycle. We have not found an 
effect of sex in our study but the number of patients included was probably not sufficient to 
analyse for a sex-by-drug effect. Further neuroendocrine studies are needed to investigate the 
effects of OT or OT receptors selective agonists in additional clinical models to promote the 
development of psychopharmacology targeting central OT receptors. 
 
Figure 1. HDRS-17 scores at days 1, 8, 15, 21 and 28 in depressive patients with intranasal synthetic OT, in 
association with antidepressant treatment 
 
Figure 2. CGI-S scores at days 1, 8, 15, 21 and 28 in depressive patients with intranasal synthetic OT, in 
association with antidepressant treatment. 
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